Market News / Story
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize…
GlobeNewswire ·
GlobeNewswire reports: First Patient Dosed with JOTROL ™ Marks Major Clinical Milestone for Jupiter Neurosciences’ Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL ™ in Patients with Parkinson’s Disease Tungsten Advisors has been retained to identify strategic options to monetize Jupiter’s existing clinical development programs via corporate partners and explore other strategic options for a transaction to maximize shareholder value Jupiter, FL, Oct. 06, 2026…